Group Profile

China Regenerative Medicine International Limited ("CRMI"), listed on The Stock Exchange of Hong Kong Limited on 18 July 2001 (Stock Code: 8158.HK), is a high-end new-technology enterprise principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of CRMI ranges among five major sectors, namely tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and overseas business division. Headquartered in Hong Kong, CRMI has seven modernized manufacturing facilities in Xi’an, Shenzhen, Suzhou, Tianjin, Changzhou and Hong Kong, and has evolved into a pioneering enterprise in tissue engineering and regenerative medicine in China.

Strive to improve and promote the quality of living and health of human beings

Strive to improve and promote the quality of living and health of human beings

Group Profile

China Regenerative Medicine International Limited ("CRMI"), listed on The Stock Exchange of Hong Kong Limited on 18 July 2001 (Stock Code: 8158.HK), is a high-end new-technology enterprise principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of CRMI ranges among five major sectors, namely tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and overseas business division. Headquartered in Hong Kong, CRMI has seven modernized manufacturing facilities in Xi’an, Shenzhen, Suzhou, Tianjin, Changzhou and Hong Kong, and has evolved into a pioneering enterprise in tissue engineering and regenerative medicine in China.